Showing 4941-4950 of 5910 results for "".
- Internal Documents Reveal COVID-19 Hospitalization Data The Government Keeps Hiddenhttps://modernod.com/news/internal-documents-reveal-covid-19-hospitalization-data-the-government-keeps-hidden/2478485/As coronavirus cases rise swiftly around the country, surpassing both the spring and summer surges, health officials brace for a coming wave of hospitalizations and deaths. Knowing which hospitals in which communities are reaching capacity could be key to an effective response to the growing cris
- Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy for Dry AMD Via Orbit SDShttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-received-investigational-gene-therapy-for-dry-amd-via-orbit-subretinal-delivery-system/2478480/Gyroscope Therapeutics announced that the first surgery using its proprietary Orbit Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been condu
- PolyActiva Appoints Tracy Valorie to its Board of Directorshttps://modernod.com/news/polyactiva-appoints-tracy-valorie-to-its-board-of-directors/2478481/PolyActiva announced the appointment of experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors. Ms. Valorie is recognized in the industry for her success in building and leading high performing teams a
- Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseaseshttps://modernod.com/news/ocumension-therapeutics-strengthens-pipeline-for-posterior-segment-eye-diseases/2478482/Ocumension Therapeutics announced that the company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology, a wholly-owned subsidiary of Luye Pharma Group, to jointly develop OT-702 (LY09004), a biosimilar to Eylea (aflibercept). Ocumension has
- Novartis Acquires Vedere Bio, Adding Novel Optogenetic Gene Therapy Technology for Treating Blindnesshttps://modernod.com/news/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-for-treating-blindness/2478474/Novartis announced that it has acquired Vedere Bio, adding a new platform for AAV-based delivery of gene therapies and an optogenetics program. The acquisition will enable Novartis to advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.
- Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countrieshttps://modernod.com/news/santen-and-aerie-conclude-exclusive-license-agreement-for-rhopressa-and-rocklatan-in-japan-and-several-other-asian-countries/2478469/Santen Pharmaceutical and Aerie Pharmaceuticals announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa and Rocklatan in Japan, along with rights for several other Asian countries. Rhopressa (netarsudil ophthalmic solution) 0
- iVeena Announces Positive Topline Results of IVMED-80 Eye Drops for Keratoconushttps://modernod.com/news/iveena-announces-positive-topline-results-of-ivmed-80-eye-drops-for-keratoconus/2478466/iVeena has announced topline results of its recently completed phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Treatment of Keratoconus.” The study objective was to determine whether a 6- or 16-week course of twice-daily IVMED-80 eyedrops (vs. placebo) coul
- AstraZeneca’s COVID-19 Vaccine Produces Robust Immune Response in Elderlyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-produces-robust-immune-response-in-elderly/2478462/AstraZeneca disclosed that its experimental COVID-19 vaccine AZD1222 triggered a robust immune response in elderly and older adults, similar to that previously seen in healthy study volunteers aged between 18 and 55. Adverse events associated with the vaccine, which is being co-developed with the
- UK Study Finds Evidence of Waning Antibody Immunity to COVID-19 Over Timehttps://modernod.com/news/uk-study-finds-evidence-of-waning-antibody-immunity-to-covid-19-over-time/2478463/Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found on Tuesday, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community, according to a Reuters
- AstraZeneca, J&J Say Their COVID-19 Vaccine Trials Back on Track in UShttps://modernod.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/AstraZeneca announced Friday that it has been cleared to restart its phase 3 COVID-19 vaccine trial in the US. The company, which is co-developing AZD1222 with the University of Oxford, had paused global testing of the vaccine candidate early last month after a UK participant fell ill with what i